And it's not just melanoma! Midkine has been implicated in metastasis for other cancers too, like breast cancer, lung cancer, colorectal cancer, and hepatocellular carcinoma. This work, therefore, has broader implications beyond just melanoma! #CancerResearch #MetastasisPrevention

Crucially, we found that combining an NR2F1 agonist with an MDK inhibitor could be a potential therapeutic strategy to prolong the dormancy phase of melanoma DCCs, preventing metastasis formation! Big implications for future treatments. #Science #CancerTreatment

This study reveals the growth factor Midkine (MDK) triggers a potent autocrine mechanism that deactivates NR2F1-dependent dormancy in DCCs, favoring metastatic outgrowth. This means MDK essentially "wakes up" dormant melanoma cells! #MIDKINE #NR2F1 #DDCs

Why is this important? Melanoma recurrence often comes from dormant cancer cells (DCCs) "waking up" to form metastases, sometime years after primary tumor was removed. We've known NR2F1 drives dormancy , but how DCCs reactivate has been puzzling. #Dormancy